+

WO2008127659A3 - Anticancer combination of a dac inhibitor and a tyrosine kinase inhibitor - Google Patents

Anticancer combination of a dac inhibitor and a tyrosine kinase inhibitor Download PDF

Info

Publication number
WO2008127659A3
WO2008127659A3 PCT/US2008/004719 US2008004719W WO2008127659A3 WO 2008127659 A3 WO2008127659 A3 WO 2008127659A3 US 2008004719 W US2008004719 W US 2008004719W WO 2008127659 A3 WO2008127659 A3 WO 2008127659A3
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
kinase inhibitor
inhibitor
wild type
romidepsin
Prior art date
Application number
PCT/US2008/004719
Other languages
French (fr)
Other versions
WO2008127659A2 (en
Inventor
Eugene P. Frenkel
Original Assignee
The Board Of Regents Of The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of The University Of Texas System filed Critical The Board Of Regents Of The University Of Texas System
Publication of WO2008127659A2 publication Critical patent/WO2008127659A2/en
Publication of WO2008127659A3 publication Critical patent/WO2008127659A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides compositions and methods for the treatment of cell proliferative disorders using at least one DAC inhibitor and at least one tyrosine kinase inhibitor. In particular, the invention provides a combination therapy for treating a proliferative disorder (e.g., cancer) including romidepsin and a tyrosine kinase inhibitor. When administered together, romidepsin and a tyrosine kinase inhibitor (e.g., erlotinib) interact to induce apoptosis. The effect is particularly pronounced in wild type non-small cell lung cancers, particularly wild type EGFR and wild type KRAS non-small cell lung cancer cells. The invention provides methods of killing malignant cells in vitro and in vivo. Pharmaceutical compositions, preparations, and kits including romidepsin and a tyrosine kinase inhibitor are also provided.
PCT/US2008/004719 2007-04-13 2008-04-11 Combination therapy for cancer WO2008127659A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92324907P 2007-04-13 2007-04-13
US60/923,249 2007-04-13

Publications (2)

Publication Number Publication Date
WO2008127659A2 WO2008127659A2 (en) 2008-10-23
WO2008127659A3 true WO2008127659A3 (en) 2009-11-05

Family

ID=39722554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/004719 WO2008127659A2 (en) 2007-04-13 2008-04-11 Combination therapy for cancer

Country Status (1)

Country Link
WO (1) WO2008127659A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006969A (en) 2006-12-29 2010-04-07 Gloucester Pharmaceuticals Preparation of romidepsin.
IL300955A (en) 2010-06-03 2023-04-01 Pharmacyclics Llc (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin 1-yl)prop-2-en-1-one for use as a medicament for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma
EP2802340B1 (en) * 2012-01-12 2020-10-28 Celgene Corporation Romidepsin formulations and uses thereof
EP3550031A1 (en) 2012-07-24 2019-10-09 Pharmacyclics, LLC Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
AU2013202507B9 (en) * 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
CN105307683A (en) * 2013-03-14 2016-02-03 基因泰克公司 Methods of treating cancer and preventing cancer drug resistance
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US10583142B2 (en) 2016-03-25 2020-03-10 OSI Pharmaceuticals, LLC Pulse dosing regimen and methods of treatment
WO2017164887A1 (en) * 2016-03-25 2017-09-28 OSI Pharmaceuticals, LLC Pulse dosing regimen and methods for treatment
GB2584441A (en) * 2019-06-03 2020-12-09 Fenomark Diagnostics Ab Medical uses, methods and uses

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004043390A (en) * 2002-07-12 2004-02-12 Nagoya Industrial Science Research Inst Antineoplastic agent
WO2004024160A1 (en) * 2002-09-13 2004-03-25 Virginia Commonwealth University Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
EP1574213A1 (en) * 2004-03-11 2005-09-14 Yih-Lin Chung Use of histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy
WO2006099396A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
WO2007039403A1 (en) * 2005-09-21 2007-04-12 Nycomed Gmbh Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
WO2007100385A2 (en) * 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004043390A (en) * 2002-07-12 2004-02-12 Nagoya Industrial Science Research Inst Antineoplastic agent
WO2004024160A1 (en) * 2002-09-13 2004-03-25 Virginia Commonwealth University Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
EP1574213A1 (en) * 2004-03-11 2005-09-14 Yih-Lin Chung Use of histone deacetylase inhibitors for increasing therapeutic gain in radiotherapy and chemotherapy
WO2006099396A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
WO2007039403A1 (en) * 2005-09-21 2007-04-12 Nycomed Gmbh Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors
WO2007100385A2 (en) * 2005-10-31 2007-09-07 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BATES DAVID: "ZD-6474. AstraZeneca", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 4, no. 12, 1 December 2003 (2003-12-01), pages 1468 - 1472, XP009050316, ISSN: 1472-4472 *
BATES S E ET AL: "Histone deacetylase inhibitors in combinations: Will the preclinical promises be kept?", CANCER JOURNAL 2007 LIPPINCOTT WILLIAMS AND WILKINS USA, vol. 13, no. 2, March 2007 (2007-03-01), pages 80 - 83, XP008111378, ISSN: 1528-9117 1540-336X *
DANCEY JANET E: "Recent advances of molecular targeted agents: opportunities for imaging.", CANCER BIOLOGY & THERAPY 2003 NOV-DEC, vol. 2, no. 6, November 2003 (2003-11-01), pages 601 - 609, XP008111441, ISSN: 1538-4047 *
DATABASE TXTJPT EUROPEAN PATENT OFFICE, THE HAGUE, NL; XP002545391 *
HIROKAWA ET AL: "Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors)", CANCER LETTERS, NEW YORK, NY, US, vol. 245, no. 1-2, 22 December 2006 (2006-12-22), pages 242 - 251, XP005813564, ISSN: 0304-3835 *
KAWANO T ET AL: "Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect", ANTICANCER RESEARCH 200409 GR, vol. 24, no. 5 A, September 2004 (2004-09-01), pages 2705 - 2712, XP008111371, ISSN: 0250-7005 *
MEHNERT J M ET AL: "Histone deacetylase inhibitors: Biology and mechanism of action", CANCER JOURNAL 2007 LIPPINCOTT WILLIAMS AND WILKINS USA, vol. 13, no. 1, January 2007 (2007-01-01), pages 23 - 29, XP008111426, ISSN: 1528-9117 1540-336X *
MORADEI O ET AL: "HISTONE DEACETYLASE INHIBITORS: LATEST DEVELOPMENTS, TRENDS AND PROSPECTS", CURRENT MEDICINAL CHEMISTRY. ANTI-CANCER AGENTS, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 5, no. 5, 1 January 2005 (2005-01-01), pages 529 - 560, XP009065870, ISSN: 1568-0118 *
NGUYEN D M ET AL: "Growth factor receptors as targets for lung cancer therapy", SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY 200403 US, vol. 16, no. 1, March 2004 (2004-03-01), pages 3 - 12, XP008111355, ISSN: 1043-0679 *
ROSATO R R ET AL: "Histone deacetylase inhibitors in clinical development", EXPERT OPINION ON INVESTIGATIONAL DRUGS 200401 GB, vol. 13, no. 1, January 2004 (2004-01-01), pages 21 - 38, XP002543980, ISSN: 1354-3784 *
SMITH P W ET AL: "Novel Targeted Therapies for Non-Small Cell Lung Cancer", THORACIC SURGERY CLINICS - THE BIOLOGY OF THORACIC SURGERY: INNOVATION IN STAGING AND TREATMENT 200611 US, vol. 16, no. 4, November 2006 (2006-11-01), pages 353 - 366, XP008111362, ISSN: 1547-4127 *
TAUCHI T ET AL: "Molecular mechanisms of resistance of leukemia to imatinib mesylate", LEUKEMIA RESEARCH 200405 GB, vol. 28, no. SUPPL. 1, May 2004 (2004-05-01), pages S39 - S45, XP005157790, ISSN: 0145-2126 *
YASUHIKO KANO ET AL: "Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 25, no. 1, 22 July 2006 (2006-07-22), pages 31 - 40, XP019434183, ISSN: 1573-0646 *
YASUI H ET AL: "Recent advances in the treatment of Multiple Myeloma", CURRENT PHARMACEUTICAL BIOTECHNOLOGY 200610 NL, vol. 7, no. 5, October 2006 (2006-10-01), pages 381 - 393, XP008111424, ISSN: 1389-2010 *
ZHANG WEI ET AL: "Histone deacetylase inhibitor FK228 enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 48, April 2007 (2007-04-01), & 98TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH; LOS ANGELES, CA, USA; APRIL 14 -18, 2007, pages 591, XP008111359, ISSN: 0197-016X *

Also Published As

Publication number Publication date
WO2008127659A2 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
WO2008127659A3 (en) Anticancer combination of a dac inhibitor and a tyrosine kinase inhibitor
Kim et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin
Zhang et al. Quercetin enhances cisplatin sensitivity of human osteosarcoma cells by modulating microRNA-217-KRAS axis
WO2008091701A3 (en) Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
MX2010006739A (en) Pyrido[2,3-b]pyrazine-8-substituted compounds and their use.
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
WO2007033023A3 (en) Compositions and methods for the diagnosis and therapy of bcl2-associated cancers
WO2006028655A3 (en) Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
PL1951729T3 (en) Oxygen linked pyrimidine derivatives
WO2003009814A3 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
NO20090623L (en) Compounds for the treatment of proliferative disorders
WO2005097137A3 (en) Advanced quinazoline based protein kinase inhibitors
WO2012135592A3 (en) Theranostic imaging agents and methods of use
WO2003097835A3 (en) Pharmaceutical compositions for the treatment of cancer
MX2010003269A (en) Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase.
NZ592326A (en) Erbb-3 (her3)-selective combination therapy
PH12022551371A1 (en) Macrocycles for use in treating disease
Longton et al. Appropriate sequence for afatinib and cisplatin combination improves anticancer activity in head and neck squamous cell carcinoma
Jain et al. Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms
WO2008035365A3 (en) Rna interference mediated inhibition of aurorakinase b and its combinations as anticancer therapy
Wu et al. Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells
WO2007126787A3 (en) Reagents and methods for cancer treatment and prevention
Matheson et al. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo
Karagülle et al. Synergistic effects of ozone with doxorubicin on the proliferation, apoptosis and metastatic profile of luminal-B type human breast cancer cell line
WO2008098183A3 (en) Combination therapy for treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742791

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/010852

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08742791

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0810837

Country of ref document: BR

Free format text: APRESENTE O COMPLEMENTO DO TEXTO EM PORTUGUES, ADAPTADO A NORMA VIGENTE, DO PEDIDO CONFORME DEPOSITO INTERNACIONAL INICIAL (RELATORIO DESCRITIVO E DESENHO SE HOUVER), CONFORME DETERMINA O ATO NORMATIVO 128/97 NO ITEM 9.2.1

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0810837

Country of ref document: BR

Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI NO 2321

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载